Discovery of Pre-Clinical Candidate VU6008055/AF98943: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy
Open Access
- 26 May 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (11) , 2141-2162
Abstract
Herein, we report the structure-activity relationship to develop novel tricyclic M4 positive allosteric modulator scaffolds with improved pharmacological properties. This endeavor involved modifying a 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide core via a "tie-back" strategy to discover a novel tricyclic 3,4-dimethylpyrimido[4',5':4,5]thieno[2,3-c]pyridazine core. From this exercise, VU6008055/AF98943 was identified as a preclinical candidate, which displays low nanomolar potency against both human and rat M4. Moreover, VU6008055 is highly brain penetrant, has an overall superior pharmacological and DMPK profile to previously reported M4 PAMs, and demonstrates efficacy in preclinical models of antipsychotic-like activity.Keywords
Funding Information
- William K. Warren Foundation (UNIV58493)
- National Institute of Mental Health (MH077607, U01MH087965, U54MH084659)
- Lundbeck Pharmaceuticals (UNIV60006)
This publication has 43 references indexed in Scilit:
- Discovery, Optimization, and Biological Characterization of 2,3,6‐Trisubstituted Pyridine‐Containing M4 Positive Allosteric ModulatorsChemMedChem, 2019
- Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M 4 positive allosteric modulator (PAM) chemotype via scaffold hoppingBioorganic & Medicinal Chemistry Letters, 2017
- Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesBioorganic & Medicinal Chemistry Letters, 2017
- Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacologyBioorganic & Medicinal Chemistry Letters, 2017
- Challenges in the development of an M 4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogsBioorganic & Medicinal Chemistry Letters, 2017
- Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophreniaBioorganic & Medicinal Chemistry Letters, 2013
- High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injuryHepatology, 2012
- Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptorBioorganic & Medicinal Chemistry Letters, 2012
- Synthesis and Structure–Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine ReceptorChemMedChem, 2009
- Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer DiseaseArchives of Neurology, 1997